NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Metrics to compare | NRXP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNRXPPeersSector | |
---|---|---|---|---|
P/E Ratio | −2.4x | −0.7x | −0.7x | |
PEG Ratio | −0.15 | 0.07 | 0.00 | |
Price/Book | −2.2x | 2.2x | 2.6x | |
Price / LTM Sales | - | 1.5x | 3.4x | |
Upside (Analyst Target) | - | 177.8% | 36.2% | |
Fair Value Upside | Unlock | 25.9% | 4.1% | Unlock |